Suzanne Cole

机构：The University of Texas Southwestern Medical Center

发表论文 4 篇 · 总被引 7 次 · h-index 1

代表论文

• Circulating tumor DNA (ctDNA) to guide response-adapted bladder preservation in muscle invasive bladder cancer (MIBC): Integrated analysis of the RETAIN trials. (2026 · Journal of Clinical Oncology · 被引 7)
• A phase III randomized trial of eribulin (E) with gemcitabine vs standard of care (SOC) for patients (pts) with metastatic urothelial carcinoma (mUC) refractory to or ineligible for PD/PDL1 antibody (Ab): SWOG S1937—Updated design. (2026 · Journal of Clinical Oncology)
• ECOG ACRIN EA8192 cohort C: A phase II trial of neoadjuvant gemcitabine/durvalumab in patients (pts) with high grade (HG) upper tract urothelial carcinoma (UTUC) ineligible for cisplatin-based chemotherapy. (2026 · Journal of Clinical Oncology)
• Induction enfortumab vedotin plus pembrolizumab followed by maintenance pembrolizumab in first-line metastatic urothelial carcinoma (IMPROEV). (2026 · Journal of Clinical Oncology)